Crizanlizumab

Drug Profile

Crizanlizumab

Alternative Names: SEG 101; Sel G1

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia

Most Recent Events

  • 31 May 2017 Novartis intends to make regulatory submissions seeking approval for Sickle cell anaemia in 2018
  • 03 Dec 2016 Efficacy and adverse events data from the SUSTAIN phase II trial in Sickle cell anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 03 Dec 2016 Final efficacy data from the phase II SUSTAIN trial in Sickle cell anaemia released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top